Key result
FDG PET-CT identifies ~53% of cardiac sarcoidosis cases missed by CMR after inconclusive imaging.
Why the study?
Cardiac sarcoidosis is underdiagnosed due to heterogeneous presentations and CMR limitations, making the added diagnostic value of FDG PET-CT following inconclusive CMR findings an important question.
Does FDG PET-CT improve the detection of cardiac sarcoidosis in patients with inconclusive CMR findings?
Does FDG PET-CT improve the detection of cardiac sarcoidosis in patients with inconclusive CMR findings?
FDG PET-CT provides significant complementary diagnostic value for cardiac sarcoidosis, identifying cases missed or misdiagnosed by CMR.
Answers are grounded in this paper and cite their sources.
May warrant FDG PET-CT after inconclusive CMR in suspected CS; extends evidence for multimodal diagnostic strategies.
Background/Introduction Cardiac sarcoidosis (CS) is frequently underdiagnosed due to its heterogeneous clinical presentation and the limitations of conventional cardiac magnetic resonance imaging (CMR). Early detection is crucial to prevent irreversible myocardial injury and optimise management. Multimodal imaging with 18F-fluorodeoxyglucose positron emission tomography–computed tomography (FDG PET-CT) can enhance diagnostic accuracy, particularly when CMR findings are inconclusive. Emerging quantitative parametric CMR techniques, such as native T1 and T2 mapping, may further improve detection as their clinical use becomes more widespread. Purpose This study evaluates the added diagnostic value of FDG PET-CT in patients with high clinical suspicion of cardiac sarcoidosis following inconclusive CMR findings in a tertiary care setting. Methods We retrospectively analysed 30 patients with suspected or biopsy-confirmed CS who underwent both CMR (including parametric mapping where available) and FDG PET-CT between 2014 and 2025. Diagnosis of cardiac sarcoidosis was established using a combination of clinical and imaging findings in accordance with contemporary guideline recommendations. Imaging findings, including quantitative mapping and FDG uptake patterns, as well as diagnostic timelines and subsequent management decisions, were reviewed and compared. Results Of the 30 patients, 19 (63%) had biopsy-confirmed cardiac sarcoidosis, and 11 (37%) had histologically confirmed systemic sarcoidosis with cardiac symptoms suggestive of CS. CMR correctly identified CS in 14 patients (47%), while FDG PET-CT identified CS in the remaining 16 patients (53%). Among these 16 patients, 12 (75%) had unremarkable CMR findings, and 4 (25%) were initially misdiagnosed with dilated or non-dilated left ventricular cardiomyopathy by CMR. Conclusions FDG PET-CT identified a considerable number of cardiac sarcoidosis cases that were not detected by CMR, highlighting the complementary value of a multimodal imaging approach. Delays in CS diagnosis may contribute to therapeutic gaps, highlighting the importance of integrating FDG PET-CT into diagnostic pathways. These findings support the use of multimodal imaging strategies and may inform future prospective studies aimed at improving sarcoidosis detection.
No takes yet. Share an insight, caveat, or question.
Baldini et al. (2026) studied this question. FDG PET-CT identified 53% of cardiac sarcoidosis cases missed by CMR in patients with inconclusive imaging, emphasizing the need for multimodal diagnostic strategies.
Synapse has enriched 10 related papers. Consider them for comparative context: